Inj, aflibercept-ayyh, 1 mg
Products billed under this code include Pavblu.
Payment limit per 1 MG, by effective quarter, 2Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Pavblu.
Payment limit per 1 MG, by effective quarter, 2Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Pavblu | Amgen Inc | 55513-0056-01 | 2 | $1,526.752 |
| Pavblu | Amgen Inc | 55513-0065-01 | 2 | $1,526.752 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $763.376 | −$39.879 | 1 MG | Inj, aflibercept-ayyh, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $803.255 | −$18.141 | 1 MG | Inj, aflibercept-ayyh, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $821.396 | −$44.807 | 1 MG | Inj, aflibercept-ayyh, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $866.203 | +$6.84 | 1 MG | Inj, aflibercept-ayyh, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $859.363 | −$9.721 | 1 MG | Inj, aflibercept-ayyh, 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $869.084 | +$73.223 | 1 MG | Inj, aflibercept-ayyh, 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $795.861 | – | 1 MG | Inj, aflibercept-ayyh, 1 mg | v1, posted March 10, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.